ACOG · XBRL financial data
Alpha Cognition financial statements, every fiscal year
The same tables from 2 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (ACOG's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Revenue | — | 10,220 |
| Cost of goods and services sold | — | 603 |
| Research and development | 3,919 | 1,868 |
| Selling, general and administrative | 8,012 | 29,076 |
| General and administrative | 7,942 | — |
| Total operating expenses | 11,861 | 32,881 |
| Operating income (loss) | (11,861) | (22,661) |
| Interest income | 162 | — |
| Interest expense | 105 | — |
| Net income (loss) | (14,637) | (20,670) |
| Earnings per share, basic USD per share | (2.02) | (1.17) |
| Earnings per share, diluted USD per share | (2.02) | (1.18) |
| Weighted average shares, basic thousands of shares | 7,248 | 17,681 |
| Weighted average shares, diluted thousands of shares | 7,248 | 17,681 |
Balance sheet
CSVFiscal years (ACOG's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Cash and cash equivalents | 48,546 | 66,047 |
| Accounts receivable | — | 4,236 |
| Inventory | 615 | 5,123 |
| Prepaid and other current assets | 1,072 | 3,545 |
| Total current assets | 50,251 | 79,010 |
| Property and equipment, net | 27 | 329 |
| Total assets | 50,737 | 79,730 |
| Accounts payable | 873 | 3,068 |
| Total current liabilities | 3,351 | 9,130 |
| Total liabilities | 9,274 | 17,200 |
| Accumulated deficit | (76,285) | (97,107) |
| Total stockholders' equity | 41,463 | 62,530 |
| Total liabilities and equity | 50,737 | 79,730 |
| Common shares outstanding (cover page) thousands of shares | 16,020 | 21,774 |
Cash flows
CSVFiscal years (ACOG's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Net income (loss) | (14,637) | (20,670) |
| Stock-based compensation | 980 | 4,923 |
| Net cash from operating activities | (7,756) | (20,380) |
| Purchases of property and equipment | 27 | 293 |
| Net cash from investing activities | (27) | (293) |
| Proceeds from issuing common stock | 3,732 | — |
| Net cash from financing activities | 54,852 | 38,215 |
| Net change in cash | 47,070 | — |
Compare with peers
SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Alpha Cognition | 41,384 | 6,093 | (6,859)* | 21.8M | 6.0 quarters | 10-QJun 30, 2026 |
| Aclaris Therapeutics | 19,167 | 1,629 | (19,847)* | 147.2M | 4.6 quarters | 10-QJun 30, 2026 |
| Sangamo Therapeutics | 27,586 | 1,442 | (19,282) | 414.3M | 1.4 quarters | 10-QMar 31, 2026 |
| Neurogene | 112,485 | not reported | (23,761)* | 20.0M | 9.5 quarters | 10-QJun 30, 2026 |
| Puma Biotechnology | 36,537 | 56,502 | 1,624* | 51.6M | — | 10-QJun 30, 2026 |
| Eledon Pharmaceuticals | 6,803 | not reported | (22,677)* | 81.3M | 3.9 quarters | 10-QJun 30, 2026 |
| Voyager Therapeutics | 35,769 | 3,165 | (25,842)* | 61.6M | 4.5 quarters | 10-QJun 30, 2026 |
| Monopar Therapeutics | 52,758 | 0* | (3,247)* | 6.7M | 32.4 quarters | 10-QJun 30, 2026 |
| Forte Biosciences | 49,629 | not reported | (22,702)* | 21.2M | 8.7 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.